Exagen Inc. Stock Price, News & Analysis

Exagen Inc. (Nasdaq: XGN) announced its participation in the Cowen 41st Annual Health Care Conference from March 1-4, 2021. Ron Rocca, President and CEO, along with CFO Kamal Adawi, will engage in a virtual fireside chat on March 3 at 4:00 pm EST. Exagen focuses on providing innovative testing solutions for autoimmune diseases to enhance diagnosis and treatment, aiming to support better patient care. Their AVISE® brand leverages proprietary technology to improve the management of conditions such as rheumatoid arthritis and lupus.

Exagen Inc. (Nasdaq: XGN) announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, scheduled for February 17-19, 2021. Key executives, including President Ron Rocca and CFO Kamal Adawi, will host a virtual fireside chat on February 17 at 3:00 PM ET. They will also engage in one-on-one meetings with investors. Exagen focuses on improving care for autoimmune disease patients through innovative testing products under its AVISE® brand.

Exagen Inc. (Nasdaq: XGN) announced that all AVISE test offerings are now an in-network service with Tufts Medical Center. This collaboration aims to enhance the accuracy and accessibility of autoimmune disease testing. John Butz from Tufts emphasized the need for better diagnostic options for autoimmunity. Ron Rocca, CEO of Exagen, noted that this agreement will significantly improve patient care through better diagnosis and monitoring capabilities. The partnership is expected to facilitate faster diagnosis and treatment interventions for complex autoimmune diseases.

Exagen Inc. (Nasdaq: XGN) reported preliminary financial results for Q4 2020, projecting testing revenue between $10.5 million and $10.8 million, reflecting an 11% to 15% increase from Q3 2020. The company delivered approximately 28,600 AVISE CTD tests, backed by a record 635 healthcare provider adopters and a 99% retention rate. Despite COVID-19 challenges, Exagen's core testing business showed strong performance, positioning it for growth in 2021. Full financial results, including SIMPONI revenue, will be released in March 2021.

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN) is set to participate in the 2021 ICR Conference from January 11-14, 2021. Ron Rocca, President and CEO, and Kamal Adawi, CFO, will hold a virtual fireside chat on January 14 at 11:30 AM ET. Attendees can schedule one-on-one meetings with management during the event. Exagen focuses on transforming care for patients with autoimmune diseases through innovative testing products, aiming to enable timely diagnosis and therapeutic intervention.

Exagen Inc. (Nasdaq: XGN) has announced that all AVISE test offerings are now contracted as in-network services with St. Charles Health System, the largest healthcare provider in Central Oregon. This partnership is expected to enhance patient care by making AVISE testing accessible to rheumatologists for the diagnosis and monitoring of autoimmune diseases, especially systemic lupus erythematosus (SLE). CEO Ron Rocca highlighted the significance of this arrangement for improving community health outcomes.

Exagen Inc. (Nasdaq: XGN) announced its participation in key December investor conferences. The Piper Sandler 32nd Annual Virtual Healthcare Conference will feature a recorded company presentation available from November 23 to December 3, 2020. Additionally, Ron Rocca, the President and CEO, will engage in a Fireside Chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 2, 2020, at 10:30 am EST. Exagen focuses on advancing care for patients with autoimmune diseases, utilizing its innovative AVISE® testing products.

Exagen Inc. (Nasdaq: XGN) has extended its collaboration agreement with GlaxoSmithKline (GSK) to improve the diagnosis of systemic lupus erythematosus (SLE), a major autoimmune disease. This partnership aims to enhance awareness of the importance of early diagnosis, which currently takes an average of nearly six years. The agreement will continue to utilize Exagen's proprietary AVISE® laboratory tests to support SLE patients in achieving better health outcomes. The details of the agreement remain confidential, following a similar extension made last year.

Exagen Inc. (Nasdaq: XGN) reported strong Q3 2020 results with revenue of $10.8 million, reflecting a 20% increase from Q2 2020 and a 3% rise year-over-year. Despite COVID-19 challenges, the company delivered 26,201 AVISE® tests and achieved a 99% retention rate among healthcare providers. Significant additions of 14 million covered lives were made, enhancing testing access. Although net loss increased to $4.3 million, gross margin improved to 60%. Exagen continues to strengthen its market position through innovative products and strategic partnerships.